Capricor Therapeutics (CAPR) Net Cash Flow Growth (3y) (2013 - 2026)
Capricor Therapeutics (CAPR) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
723,416.35 Bn |
723,416.32 Bn |
- |
- |
| 2 |
Belite Bio |
57,340.00 Bn |
57,340.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
19,125.08 Bn |
19,125.08 Bn |
- |
- |
| 4 |
Legend Biotech |
3,262.00 Bn |
3,261.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,789.67 Bn |
1,789.67 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,480.39 Bn |
1,480.37 Bn |
- |
- |
| 7 |
Psyence Biomedical |
241.78 Bn |
241.78 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.54 Bn |
106.29 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
94.26 Bn |
94.26 Bn |
- |
- |
| 10 |
Capricor Therapeutics |
1.53 Bn |
1.26 Bn |
- |
-468.78% |
| Date | Value |
| Mar 31, 2026 |
-468.78% |
| Dec 31, 2025 |
508.73% |
| Sep 30, 2025 |
22.39% |
| Jun 30, 2025 |
49.03% |
| Mar 31, 2025 |
-9.28% |
| Dec 31, 2024 |
-112.45% |
| Sep 30, 2024 |
175.42% |
| Jun 30, 2024 |
47.00% |
| Mar 31, 2024 |
-42.94% |
| Dec 31, 2023 |
60.93% |
| Sep 30, 2023 |
3.62% |
| Jun 30, 2023 |
-26.69% |
| Mar 31, 2023 |
-52.44% |
| Dec 31, 2022 |
33.44% |
| Sep 30, 2022 |
-119.12% |
| Jun 30, 2022 |
-224.12% |
| Mar 31, 2022 |
102.82% |
| Dec 31, 2021 |
-186.03% |
| Sep 30, 2021 |
49.38% |
| Jun 30, 2021 |
-60.59% |